The FDA has released a batch of noncompliance letters taking drugmakers to task for failing to meet certain requirements for testing and seeking approval of pediatric formulations. The move is an effort to shame drugmakers that fail to comply with the Pediatric Research Equity Act, Ed Silverman writes.

Full Story:

Related Summaries